Skip to main content
    R

    Rhythm Pharmaceuticals Inc (RYTM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $86.61
    -3.21 (-3.57%)

    Market Cap: $6.00B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(23/36)
    Avg Surprise
    -14.46%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.75
    Range$-0.85 - $-0.66
    12 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.82+8.8%
    60d ago$-0.75+0.1%
    30d ago$-0.75+0.2%
    7d ago$-0.76+1.5%
    Current$-0.75
    Revenue Consensus
    $84M
    Range$78M - $93M
    16 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.63
    Range$-0.91 - $-0.38
    12 analysts
    Revenue Consensus
    $107M
    Range$91M - $128M
    16 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.63---
    Sep 26EST
    		-$-0.75---
    Jun 26
    Reported Aug 4
    		$-0.73$-0.81+9.88%Beat+2.7%
    Mar 26
    Reported May 5
    		$-0.83$-0.86+3.49%Beat-2.5%
    Dec 25
    Reported Feb 26
    		$-0.73$-0.79+7.59%Beat-1.4%
    Sep 25
    Reported Nov 4
    		$-0.82$-0.73-12.33%Miss-12.3%
    Jun 25
    Reported Aug 5
    		$-0.75$-0.67-11.94%Miss-36.4%
    Mar 25
    Reported May 7
    		$-0.81$-0.68-19.12%Miss+65.5%
    Dec 24
    Reported Feb 26
    		$-0.72$-0.73+1.37%Beat-2.9%
    Sep 24
    Reported Nov 5
    		$-0.73$-0.87+16.09%Beat+3.9%
    Jun 24
    Reported Aug 6
    		$-0.55$-0.72+23.61%Beat+32.9%
    Mar 24
    Reported May 7
    		$-2.35$-2.39+1.67%Beat-155.4%
    Dec 23
    Reported Feb 22
    		$-0.70$-0.70+0.00%Beat+6.7%
    Sep 23
    Reported Nov 7
    		$-0.76$-0.76+0.00%Beat+3.8%
    Jun 23
    Reported Aug 1
    		$-0.82$-0.78-5.13%Miss+7.9%
    Mar 23
    Reported May 2
    		$-0.92$-0.77-19.48%Miss+12.4%
    Dec 22
    Reported Mar 1
    		$-0.75$-0.81+7.41%Beat+11.8%
    Sep 22
    Reported Nov 8
    		$-0.79$-0.98+19.39%Beat-12.9%
    Jun 22
    Reported Aug 2
    		$-0.89$-1.03+13.59%Beat-27.1%
    Mar 22
    Reported May 3
    		$-1.05$-1.04-0.96%Miss+9.5%
    Dec 21
    Reported Mar 1
    		$-0.85$-0.91+6.59%Beat-7.6%
    Sep 21
    Reported Nov 2
    		$-0.70$-0.83+15.66%Beat+9.1%
    Jun 21
    Reported Aug 3
    		$-0.70$-0.74+5.41%Beat+1.4%
    Mar 21
    Reported May 3
    		$-1.16$0.30-486.67%Miss-48.7%
    Dec 20
    Reported Mar 1
    		$-0.79$-0.79+0.00%Beat-1.3%
    Sep 20
    Reported Nov 2
    		$-0.77$-0.80+3.75%Beat+26.0%
    Jun 20
    Reported Aug 3
    		$-0.71$-0.82+13.41%Beat+42.7%
    Mar 20
    Reported May 4
    		$-0.78$-0.82+4.88%Beat+7.1%
    Dec 19
    Reported Mar 2
    		$-0.78$-0.89+12.36%Beat-5.4%
    Sep 19
    Reported Nov 1
    		$-1.04$-1.10+5.45%Beat-100.0%
    Jun 19
    Reported Jul 29
    		$-1.24$-0.85-45.88%Miss-138.5%
    Mar 19
    Reported May 3
    		$-0.84$-0.73-15.07%Miss-40.0%
    Dec 18
    Reported Mar 8
    		$-0.74$-0.57-29.82%Miss-80.5%
    Sep 18
    Reported Nov 9
    		$-0.52$-0.61+14.75%Beat+21.2%
    Jun 18
    Reported Aug 8
    		$-0.52$-0.47-10.64%Miss-26.8%
    Mar 18
    Reported May 14
    		$-0.60$-0.42-42.86%Miss-106.9%
    Dec 17
    Reported Mar 12
    		$-0.41$-0.46+10.87%Beat-
    Sep 17
    Reported Oct 5
    		$-0.66$-0.56-17.86%Miss-
    Jun 17
    Reported Aug 30
    		$-0.41$0.00N/AMiss-
    Mar 17
    Reported May 24
    		$-0.29$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-27.85EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-85.60%Operating Margin-68.10%
    ROE-117.10%ROIC-96.13%
    Financial Health
    Debt/Equity1.03xInterest Coverage-10.88x
    Current Ratio3.45xQuick Ratio3.20x
    Trading Statistics
    Beta2.01Avg Volume823.59K
    52-Week High$122.2052-Week Low$74.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$91.00
    SMA 20$94.61
    SMA 50$103.37
    SMA 200$98.10
    EMA 10$91.04
    EMA 20$94.21
    EMA 50$99.17
    EMA 200$98.06

    MACD

    Line: -4.02Signal: -3.61Hist: -0.40

    ADX

    ADX: 37.8+DI: 9.9-DI: 29.3

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down100.0
    PSAR$92.34

    Bollinger Bands

    Upper Band$102.94
    Lower Band$86.29
    %B Position1759%(Upper)
    Band Width0.02

    RSI (14-Day)

    Oversold
    25.7

    Momentum Oscillators

    Stoch %K16.3
    Stoch %D17.6
    Williams %R-98.0
    ROC (10d)-9.5%
    Momentum-9.10
    CCI (20d)-135.8
    MFI (14d)19.2

    Volatility Measures

    ATR (14d)$3.73(4.3%)
    StdDev (20d)4.16
    Hist Vol23.4%(Moderate)

    Volume Flow

    VWAP$87.82
    OBV19.9M
    AD Line2.5M
    CMF (20d)-0.291

    Volume Metrics

    Avg Vol (20d)820.7K
    Vol Ratio0.8x
    VWMA (20d)$94.37

    Pivot Points

    R3$92.92
    R2$92.17
    R1$91.00
    Pivot Point$90.24
    S1$89.07
    S2$88.31
    S3$87.14

    Advanced Oscillators

    TSI-39.92
    Ultimate Osc34.4
    KST-128.19

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$71.25M$60.11M$57.25M$51.30M$48.50M$32.70M$41.83M$33.25M$29.08M$25.97M$24.23M$22.50M
    Cost of Revenue$8.93M$7.16M$4.80M$5.50M$5.54M$3.65M$3.79M$3.83M$2.95M$2.81M$3.23M$2.41M
    Gross Profit$62.32M$52.95M$52.45M$45.80M$42.96M$29.06M$38.04M$29.42M$26.13M$23.16M$21.00M$20.09M
    Operating Expenses$110.88M$105.32M$99.51M$98.45M$88.25M$76.06M$79.30M$73.31M$66.61M$163.05M$62.27M$64.05M
    R&D$43.43M$41.73M$42.03M$46.03M$42.31M$36.97M$41.17M$37.93M$30.19M$128.66M$29.89M$33.57M
    SG&A$67.45M$63.59M$57.48M$52.42M$45.95M$39.09M$38.13M$35.38M$36.41M$34.38M$32.38M$30.48M
    Operating Income$-48,552,000$-52,361,000$-47,063,000$-52,653,000$-45,296,000$-47,004,000$-41,253,000$-43,885,000$-40,478,000$-139,887,000$-41,269,000$-43,953,000
    Interest Income$3.22M$3.55M$4.08M$4.33M$3.24M$3.64M$3.51M$4.05M$4.10M$3.05M$3.82M$3.47M
    Interest Expense$4.54M$4.58M$4.62M$4.74M$5.82M$5.41M$6.00M$5.24M$4.60M$4.75M$4.38M$3.15M
    Income Before Tax$-48,854,000$-55,094,000$-47,536,000$-52,793,000$-46,295,000$-49,418,000$-43,417,000$-43,985,000$-31,782,000$-141,072,000$-41,437,000$-43,795,000
    Income Tax Expense$444,000$545,000$-31,000$111,000$337,000$80,000$-89,000$-344,000$479,000$300,000$196,000$368,000
    Net Income$-49,298,000$-55,639,000$-47,505,000$-52,904,000$-46,632,000$-49,498,000$-43,328,000$-43,641,000$-32,261,000$-141,372,000$-41,633,000$-44,163,000
    EBITDA$-48,457,000$-55,249,000$-48,588,000$-53,770,000$-44,520,000$-49,052,000$-42,683,000$-44,877,000$-33,078,000$-140,328,000$-50,294,000$-39,371,000
    EBIT$-47,534,000$-54,065,000$-47,005,000$-52,379,000$-43,720,000$-47,648,000$-40,928,000$-42,797,000$-31,276,000$-139,363,000$-40,876,000$-44,112,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RYTM

    News

    JPMorgan cuts target for Rhythm Pharmaceuticals stock to USD 145.00

    JPMorgan has lowered its price target for Rhythm Pharmaceuticals (RYTM) stock to $145.00 from $146.00, while maintaining an "Overweight" rating. This adjustment follows the company's second-quarter revenue of $71.26...

    ad-hoc-news.de•10/15/26•Somewhat-Bearish

    Citi Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $143

    Citi has reiterated its Buy rating for Rhythm Pharmaceuticals (RYTM.US) and maintained its target price at $143. This indicates continued confidence from the firm in the pharmaceutical company's future performance.

    Moomoo•10/15/26•Bullish

    Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity By Investing.com

    Rhythm Pharmaceuticals Inc. has launched IMCIVREE (setmelanotide) in Japan for the treatment of acquired hypothalamic obesity...

    Investing.com Nigeria•10/14/26•Bullish

    Rhythm Pharmaceuticals Announces Commercial Launch of

    Rhythm Pharmaceuticals has commercially launched IMCIVREE (setmelanotide) in Japan for patients with acquired hypothalamic obesity (HO). This marks the first approved therapy in Japan for this condition...

    GlobeNewswire•10/14/26•Bullish

    Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity

    Rhythm Pharmaceuticals has launched IMCIVREE (setmelanotide) in Japan for treating acquired hypothalamic obesity...

    Investing.com•10/13/26•Bullish

    RYTM Valuation and Fair Value

    P/E
    -27.8x
    Forward P/E
    526.3x
    P/B
    57.7x
    See GNG's fair value

    RYTM Profitability: Margins, ROIC and FCF

    Gross margin
    89.0%
    Operating margin
    -68.1%
    Net margin
    -85.6%
    ROIC
    -96.1%
    ROE
    -117.1%
    FCF margin
    -44.3%

    RYTM Competitors

    CompanyTicker
    Kiniksa Pharmaceuticals LtdKNSA
    Ligand Pharmaceuticals IncorporatedLGND
    Centessa Pharmaceuticals PLC ADRCNTA
    Immunovant IncIMVT
    GRAIL, LLCGRAL
    Kodiak Sciences IncKOD
    Iovance Biotherapeutics IncIOVA
    Haemonetics CorporationHAE

    Sector: Healthcare

    RYTM Analyst Ratings

    Consensus
    Buy
    Analysts
    18
    Strong Buy
    5
    Buy
    11
    Hold
    2
    Sell
    0
    Strong Sell
    0

    RYTM Bull Case vs Bear Case

    Bull case

    • RYTM grew quarterly revenue 46.9% year over year.
    • 88.9% of RYTM's analyst ratings are Buy or Strong Buy.

    Bear case

    • RYTM has a -85.6% net profit margin.

    RYTM Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    -0.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.75
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About RYTM

    Does RYTM pay dividends?

    Rhythm Pharmaceuticals Inc (RYTM) does not currently pay a regular dividend.

    What is RYTM's market cap?

    Rhythm Pharmaceuticals Inc (RYTM) has a market capitalization of $6.00B with a current stock price of $86.61.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In